Werewolf Therapeutics, Inc. HOWL 深 滬
等待開盤 09-11 09:30:00 美东时间
1.41
+0.040
+2.92%
華盛通- 最 高1.49
- 今 開1.37
- 成交量 42.63万股
- 最 低 1.35
- 昨 收 1.37
- 總市值 6327.18万
- 52周最高 4.18
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.595
- 委 比 97.86%
- 總股本 4487.36万
- 歷史最高 23.99
- 量 比 3.32
- 振 幅 10.22%
- 歷史最低 0.595
- 每 手 1
- 風險率 1.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Werewolf Therapeutics, Inc., a biopharmaceutical company, announced that its President and CEO, Daniel J. Hicklin, Ph.D., and Chief Medical Officer, Randi Isaacs, M.D., will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The event will be webcast live with an archive available for 90 days. The company specializes in developing immune-stimulating therapeutics for cancer and immu...
09-02 12:00
美股大行评级 | 潜在涨幅17.9%！Stifel维持英伟达"买入"评级，目标价升至212美元；美银首予Figma"中性"评级，目标价85美元
今日重点评级关注：Stifel：维持英伟达"买入"评级，目标价从202美元升至212美元；蒙特利尔银行：维持Sabra Health Care REIT"与大市齐平"评级，目标价从19美元升至22美元
08-26 10:29
JMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $3
JMP Securities analyst Reni J. Benjamin maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and lowers the price target from $4 to $3.
08-21 21:11
Werewolf Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 17.36 percent. This is a 6.98 percent increase over losses of $(0.43) per share
08-14 19:18
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics provides updates on its clinical trials, including interim data readouts for WTX-124 in late 2025 and plans to engage with FDA for registrational pathways. WTX-330's Phase 1b/2 trial is enrolling, with dosing regimen to be determined by year-end. The company introduces WTX-1011, its first INDUCER T-cell engager targeting STEAP1 for prostate cancer, showcasing promising preclinical data. Financially, the company has $77.6 mil...
08-14 11:00
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics' Chief Medical Officer, Randi Isaacs, will speak at the KidneyCAN 7th Annual Summit on July 17-18 in Boston. Her presentation will focus on the company's innovative approach to conditionally activated cytokines, specifically WTX-124, a tumor-activated IL-2 molecule designed to enhance anti-tumor activity while reducing systemic side effects. The company is currently enrolling patients in a clinical trial for advanced or meta...
07-09 12:00
Werewolf Therapeutics Adopts New Bylaws and Elects Directors
An update from Werewolf Therapeutics ( ($HOWL) ) is now available. On June 12, ...
06-14 04:42
Werewolf Therapeutics to Participate in the BIO International Convention
Werewolf Therapeutics' Chief Medical Officer, Randi Isaacs, will participate in a panel discussion at the BIO International Convention on 'Conditionally Active Biologics' to explore their potential in reducing systemic toxicity while enhancing anti-tumor activity. The company highlights its INDUKINE molecules, with WTX-124 showing promising results, including a patient with cutaneous squamous cell carcinoma in remission for over a year. Werewolf ...
06-12 12:00
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Werewolf Therapeutics, Inc. announced that its President and CEO, Daniel J. Hicklin, Ph.D., and Chief Medical Officer, Randi Isaacs, M.D., will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, during the Jefferies Global Healthcare Conference. A live webcast will be accessible at [link] and an archived replay will be available for 90 days. The company, focused on developing conditionally activated therapeutics to stimulate...
05-29 12:00
Patient With Advanced Skin Cancer In Remission Over Year After Clinical Trial Of Werewolf Therapeutics' investigational Novel Conditionally Activated IL-2 pro-Drug WTX-124
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threateningSkin Cancer Awareness Month in May shines a spotlight on the
05-21 04:03
